Patients with breast cancers exhibiting high-level expression of ROR2 did not have a significant difference in EFS compared to patients with tumors with low-level expression of ROR2 when adjusted for subtype and treatment arm (HR = 1.09, 95% CI = 0.94–1.27, LRp = 0.27), Table 1. This evidence concerns the gene ROR2 and breast cancer.